177Lu是一种治疗性核素,而激素治疗可增加PSMA的表达和放射敏感性。因此在这项由美国国防部资助的研究中,我们假设177Lu-J591与酮康唑(keto)和氢化可的松(HC)联用靶向PSMA治疗非转移性去势抵抗性前列腺癌(nmCRPC),可获得较111In更好...
177lu radiolabeled anti-psma monoclonal antibody j591Clinical trial has received WCMC IRB and CTSC approval with enrollment of initial 5 subjects at WCMC. An additional 33 subjects enrolled (28 treated) at participating sub-sites. Reports submitted to WCMC DSMB in July 2014 with approval to ...
PSMA 是68Ga-PSMA-11 用于显像和177Lu-PSMA- 617用于治疗 的共同分子基础,PSMA-617 表现出 更高的 亲和力和内化效率,动物实验显示,177Lu- PSMA-617标 记肿瘤病灶具有更高的靶/本 底比值[13],因此是性能优良的 RLT 探针. PSMA 单克隆 抗体 (J591)由于相对分子质量较大 ,血液清除慢 ,对肿瘤组织渗透性差...
177Lu-J591; 117Lu-J591; 177Lu−J591; lutetium Lu 177 monoclonal antibody J591; TX591; TLX591; 177Lu-DOTA-Rosopatamab; 177Lu-DOTA-TLX591-CHO; 177Lu-DOTA-rosopatamb; 177Lu-TLX591; 177Lu-DOTA-TLX591 药品类别 创新药; 生物; 抗体; potential first-in-class; 放射性药物; 偶联药物...
J591 mAb was labeled with 177 at a high specific activity (10-30 mCi/mg) using DOTA as the bifunctional chelate. The preclinical data in PSMA positive xenografts, strongly suggested that 177 mAb is an ideal radiopharmaceutical for RIT of metastatic PCa. Since October 2000, five clinical ...
Phase 1 and 2 trials of single dose 177Lu-J591 are published. We conducted two phase 1 dose escalation studies of fractionated dose 177Lu-J591 to test hypothesis that higher cumulative radiation doses can be safely administered. METHODS Initially, phase 1 dose escalation study of 177Lu-J591...
Phase II trial of (177)lutetium radiolabeled anti-PSMA antibody J591 (Lu-177-J591) for metastatic castrate-resistant prostate cancer (metCRPC): Survival update and expansion cohort with biomarkers. J Clin Oncol. 2013;31(Suppl:S),... ST Tagawa,NH Akhtar,J Osborne,... - 《Journal of Cli...
Abuqbeitah M, Demir M, Uslu-Beşli L, et al. Blood clearance and occupational exposure for177Lu-DOTATATE compared to177Lu-PSMA radionuclide therapy[J].Radiat Environ Biophys,2018,57(1): 55- 61. https://doi.org/10.1007/s00411-017-0721-6 ...
Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kürpig S, Eppard E, et al. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617. Eur J Nucl Med Mol Imaging. 2017;44(9):1448–54. ...
摘要: Aim In this study, we want to compare the efficacy and toxicity of 177 Lu-J591 PSMA antibody with the 177 Lu-DKFZ-617 PSMA ligand.DOI: 10.13140/RG.2.2.35588.73601 年份: 2016 收藏 引用 批量引用 报错 分享 全部来源 免费下载 求助全文 ResearchGate ResearchGate (全网免费下载) 相似文献 ...